• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aniline and substituted anilines Sulfonylanilines

Research Brief on Benzenamine, 4-(methylsulfonyl)-2-(trifluoromethyl)- (CAS: 55080-84-7) in Chemical Biomedicine

Benzenamine, 4-(methylsulfonyl)-2-(trifluoromethyl)- (CAS: 55080-84-7) is a specialized chemical compound that has garnered significant attention in the field of chemical biomedicine due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a pharmacophore in drug development.

Recent studies have highlighted the compound's role as a key intermediate in the synthesis of novel anti-inflammatory and anticancer agents. The trifluoromethyl and methylsulfonyl functional groups contribute to enhanced metabolic stability and improved binding affinity to biological targets. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its effectiveness as a COX-2 inhibitor scaffold, showing promising selectivity over COX-1 in preclinical models.

Advanced computational modeling approaches have been employed to understand the compound's interaction with various biological targets. Molecular docking studies reveal that the 4-(methylsulfonyl) group forms critical hydrogen bonds with amino acid residues in the active sites of target proteins, while the trifluoromethyl group contributes to hydrophobic interactions and improved membrane permeability.

The compound's pharmacokinetic properties have been investigated in several recent studies. Research published in Drug Metabolism and Disposition (2024) indicates favorable absorption characteristics and moderate plasma protein binding, making it a viable candidate for further drug development. However, challenges remain in optimizing its metabolic stability, as the compound shows susceptibility to hepatic glucuronidation in some models.

Emerging applications in targeted cancer therapy have been particularly noteworthy. A 2024 study in Molecular Cancer Therapeutics demonstrated that derivatives of 55080-84-7 show selective inhibition of certain kinase pathways involved in tumor proliferation. The compound's ability to modulate the tumor microenvironment through inhibition of specific inflammatory mediators is currently under investigation in multiple preclinical models.

Recent synthetic chemistry advancements have improved the yield and purity of Benzenamine, 4-(methylsulfonyl)-2-(trifluoromethyl)- production. A novel catalytic system developed in 2023 allows for more efficient introduction of the trifluoromethyl group while minimizing unwanted byproducts. These process improvements have significant implications for scaling up production for potential clinical applications.

Ongoing research is exploring the compound's potential in combination therapies. Preliminary data suggests synergistic effects when used with certain immunomodulators, though detailed mechanism-of-action studies are still needed. The compound's safety profile is currently being evaluated in extended toxicology studies, with initial results expected in late 2024.

In conclusion, Benzenamine, 4-(methylsulfonyl)-2-(trifluoromethyl)- (55080-84-7) represents a promising scaffold in medicinal chemistry with diverse therapeutic potential. Continued research into its structure-activity relationships and mechanism of action will be crucial for translating these findings into clinical applications. The compound's unique combination of chemical properties positions it as a valuable tool for developing next-generation therapeutics in inflammation and oncology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)